The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.

Italian biotech Aptadir Therapeutics has launched with the promise that its pipeline of preclinical RNA inhibitors could ...

Aptadir Therapeutics, a biotech focused on RNA inhibitor therapies for cancer and genetic conditions, has launched with $1.6 ...

Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable ...

What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient ...

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

Stem cell transplant is a promising treatment option for patients with myelodysplastic syndrome (MDS). Still, the decision to ...

Learn more about whether Arcellx Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on AAII's A+ Investor ...

Researchers sought to assess the reporting of patient-reported outcomes in associated clinical trial publications.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...